ArticleThe oncologist2025

Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer.

Alexis LeVee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.